EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Evommune, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.27+0.10 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $190.43M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$13.14 (−71.37%)since Nov 7, 2025
Weekly closes, adjusted for splits, on a log scale. Drag across the chart to measure a change.
Evommune, Inc. reported revenue of $10.00M for the twelve months to Jun 30, 2026. Free cash flow was -$74.65M.
Revenue
$10.00M
TTM Q2 2026
Operating income
-$101.89M
TTM Q2 2026
Free cash flow
-$74.65M
TTM Q2 2026
EPS, diluted
-$11.22
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $190.43M
- P/E ratio
- –
- Price to sales
- 19.04
- Price to book
- 0.69
- Dividend yield
- –
- Free cash flow yield
- -39.20%
Fundamentals
- Revenue
- $10.00M
- Net income
- -$94.67M
- EPS, diluted
- -$11.22
- Free cash flow
- -$74.65M
- Book value per share
- $7.68
- Diluted shares
- 36M
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Revenue
$10.00M
Operating income
-$101.89M
Net income
-$94.67M
EPS, diluted
–
Free cash flow
-$74.65M
Reported periodTrailing twelve months